Given the broad range of potential indications, Cypralis seeks to establish collaborations with pharma and biotech companies to develop cyclophilin inhibitors for a number of acute and chronic diseases. Please contact us to explore opportunities for potential evaluation of Cypralis compounds under MTA.
Gilead Sciences, Inc.
Cypralis has an existing agreement with Gilead Sciences, Inc. (Foster City, California) following a multi-year drug discovery collaboration between Selcia Ltd (Ongar, Essex) and Gilead. Selcia and Gilead signed a drug discovery collaboration agreement in 2008 under which Selcia’s chemists and biologists provided integrated drug discovery services to support Gilead’s liver disease research programmes. During the research collaboration, Selcia and Gilead generated four jointly owned patents and two pre-clinical candidates. The research phase ended in 2013 and Selcia’s rights under the agreement have been subsequently transferred to Cypralis. Gilead and Cypralis continue to conduct research using the knowledge estate.
Janssen Pharmaceuticals, Inc.
Cypralis has a collaboration with Janssen Pharmaceuticals Inc, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop new cyclophilin inhibitors for neurodegenerative diseases. Cypralis and Janssen are undertaking a joint research program to generate a new class of CNS penetrant, selective inhibitors of cyclophilin D applicable to targeting degenerative diseases including CNS degeneration. The medicinal chemistry and PPIase screening are sub-contracted to Selcia Limited. The collaboration was announced on 7th December 2015. See news article.
Alzheimer’s Drug Discovery Foundation (ADDF)
Cypralis has received funding from ADDF to extend its ‘hit-to-lead’ medicinal chemistry programme with the goal of developing a novel class of cyclophilin D inhibitors for neurodegenerative diseases. Many previous publications have recognised the potential for cyclophilin D as a novel target for degenerative disease but no group has previously published on compounds which successfully target cyclophilin D and penetrate the brain. The collaboration was announced on 1st March 2017. See news article.
Please contact us to explore opportunities for collaboration or investment.